[Journal logo]

Volume 68 
Part 1 
Pages o87-o88  
January 2012  

Received 30 November 2011
Accepted 5 December 2011
Online 10 December 2011

Key indicators
Single-crystal X-ray study
T = 296 K
Mean [sigma](C-C) = 0.003 Å
R = 0.055
wR = 0.185
Data-to-parameter ratio = 21.4
Details
Open access

Ethyl 2-(4-hydroxy-3-methoxyphenyl)-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-benzimidazole-5-carboxylate monohydrate

aInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden 11800, Penang, Malaysia, and bSchool of Physics, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia
Correspondence e-mail: arazaki@usm.my

In the title compound, C24H27N3O5·H2O, the essentially planar benzimidazole ring system [maximum deviation = 0.020 (1) Å] forms dihedral angles of 54.10 (11) and 67.79 (6)°, respectively, with the mean plane of pyrrolidin-2-one ring and the benzene ring. The pyrrolidin-2-one ring adopts an envelope conformation with one of the methylene C atoms at the flap. An intramolecular C-H...[pi] interaction is observed. In the crystal, O-H...O and O-H...N hydrogen bonds link the two components into a double-tape structure along the a axis. The crystal packing is further stabilized by weak [pi]-[pi] stacking [centroid-centroid distance = 3.6632 (9) Å] and C-H...O interactions.

Related literature

For the biological activity of benzimidazole derivatives, see: Rao et al. (2002[Rao, A., Chimirri, A., Clercq, E. D., Monforte, A. M., Monforte, P., Pannecouque, C. & Zappala, M. (2002). Farmaco, 57, 819-823.]); Thakurdesai et al. (2007[Thakurdesai, P. A., Wadodkar, S. G. & Chopade, C. T. (2007). Pharmacol. Online, 1, 314-329.]); Dubey & Sanyal (2010[Dubey, A. K. & Sanyal, P. K. (2010). Vet Scan, 5, 63.]). For related structures, see: Yoon et al. (2011[Yoon, Y. K., Ali, M. A., Wei, A. C., Quah, C. K. & Fun, H.-K. (2011). Acta Cryst. E67, o2405.]). For the ring conformation, see: Cremer & Pople (1975)[Cremer, D. & Pople, J. A. (1975). J. Am. Chem. Soc. 97, 1354-1358.].

[Scheme 1]

Experimental

Crystal data
  • C24H27N3O5·H2O

  • Mr = 455.50

  • Triclinic, [P \overline 1]

  • a = 9.7460 (8) Å

  • b = 10.0436 (8) Å

  • c = 12.6072 (10) Å

  • [alpha] = 85.737 (1)°

  • [beta] = 89.684 (2)°

  • [gamma] = 70.238 (1)°

  • V = 1157.91 (16) Å3

  • Z = 2

  • Mo K[alpha] radiation

  • [mu] = 0.10 mm-1

  • T = 296 K

  • 0.43 × 0.32 × 0.16 mm

Data collection
  • Bruker APEXII DUO CCD area-detector diffractometer

  • Absorption correction: multi-scan (SADABS; Bruker, 2009[Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.]) Tmin = 0.960, Tmax = 0.985

  • 18195 measured reflections

  • 6686 independent reflections

  • 4485 reflections with I > 2[sigma](I)

  • Rint = 0.029

Refinement
  • R[F2 > 2[sigma](F2)] = 0.055

  • wR(F2) = 0.185

  • S = 1.07

  • 6686 reflections

  • 312 parameters

  • H atoms treated by a mixture of independent and constrained refinement

  • [Delta][rho]max = 0.30 e Å-3

  • [Delta][rho]min = -0.26 e Å-3

Table 1
Hydrogen-bond geometry (Å, °)

Cg4 is the centroid of the C8-C13 benzene ring.

D-H...A D-H H...A D...A D-H...A
O1W-H2W1...O2i 0.85 (3) 2.06 (3) 2.879 (2) 164 (2)
O1W-H1W1...N1ii 0.95 (3) 1.90 (3) 2.8416 (19) 176 (2)
O4-H1O4...O1W 0.88 (3) 1.80 (3) 2.675 (2) 169 (3)
C16-H16A...O5iii 0.96 2.44 3.380 (3) 166
C20-H20B...Cg4 0.97 2.86 3.750 (3) 153
Symmetry codes: (i) -x, -y+1, -z+1; (ii) -x+1, -y+1, -z+1; (iii) x-1, y, z-1.

Data collection: APEX2 (Bruker, 2009[Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.]); cell refinement: SAINT (Bruker, 2009[Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.]); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009[Spek, A. L. (2009). Acta Cryst. D65, 148-155.]).


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: IS5022 ).


Acknowledgements

The authors thank the Malaysian Government and Universiti Sains Malaysia for the Research University Grant Nos. 1001/PFIZIK/811151 and 1001/PSK/8620012. The authors also wish to express their thanks to the Pharmacogenetic and Novel Therapeutic Research, Institute for Research in Molecular Medicine, Universiti of Sains Malaysia.

References

Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
Cremer, D. & Pople, J. A. (1975). J. Am. Chem. Soc. 97, 1354-1358.  [CrossRef] [ChemPort] [ISI]
Dubey, A. K. & Sanyal, P. K. (2010). Vet Scan, 5, 63.
Rao, A., Chimirri, A., Clercq, E. D., Monforte, A. M., Monforte, P., Pannecouque, C. & Zappala, M. (2002). Farmaco, 57, 819-823.  [CrossRef] [PubMed] [ChemPort]
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [details]
Spek, A. L. (2009). Acta Cryst. D65, 148-155.  [ISI] [CrossRef] [details]
Thakurdesai, P. A., Wadodkar, S. G. & Chopade, C. T. (2007). Pharmacol. Online, 1, 314-329.
Yoon, Y. K., Ali, M. A., Wei, A. C., Quah, C. K. & Fun, H.-K. (2011). Acta Cryst. E67, o2405.  [CSD] [CrossRef] [details]


Acta Cryst (2012). E68, o87-o88   [ doi:10.1107/S1600536811052391 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.